| Literature DB >> 30273184 |
Rebecca G Baker, Axel X Hoos1, Stacey J Adam2, David Wholley2, James H Doroshow3, Douglas R Lowy3, Lawrence A Tabak, Francis S Collins.
Abstract
As a part of the Cancer Moonshot, the National Cancer Institute, part of the National Institutes of Health, the Foundation for National Institutes of Health, the US Food and Drug Administration, and 12 pharmaceutical companies have formed a 5-year, $220 million precompetitive public-private research collaboration called the Partnership for Accelerating Cancer Therapies. A systematic cross-sector effort to identify and develop robust, standardized biomarkers and related clinical data, Partnership for Accelerating Cancer Therapies will support the selection and testing of promising immunotherapies for the treatment of cancer, with the goal of bringing effective therapy to more patients.Entities:
Mesh：
Substances：
Year: 2018 PMID： 30273184 PMCID： PMC6170010 DOI： 10.1097/PPO.0000000000000321
Source DB: PubMed Journal: Cancer J ISSN： 1528-9117 Impact factor: 3.360